Targeted agents for the treatment of advanced renal cell carcinoma (Q36293115)

13 August 2017

1 reference

title

Targeted agents for the treatment of advanced renal cell carcinoma. (English)

1 reference

13 August 2017

Walter M Stadler

1

1 reference

13 August 2017

language of work or name

English

0 references

publication date

1 December 2005

1 reference

13 August 2017

1 reference

13 August 2017

volume

104

1 reference

13 August 2017

issue

11

1 reference

13 August 2017

page(s)

2323-2333

1 reference

Cytotoxic chemotherapy for metastatic renal cell carcinoma

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21453

Expression levels of genes that regulate metastasis and angiogenesis correlate with advanced pathological stage of renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21453

A Tumor Suppressing Duo: TGFβ and Activin Modulate a Similar Transcriptome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21453

Metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21453

7 January 2021

Evaluation of low dose continuous infusion 5-fluorouracil in patients with advanced and recurrent renal cell carcinoma. A Southwest Oncology Group Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21453

7 January 2021

Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21453

7 January 2021

Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21453

7 January 2021

Rising incidence of renal cell cancer in the United States

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21453

7 January 2021

Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21453

7 January 2021

Mutation and cancer: statistical study of retinoblastoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21453

7 January 2021

Statistical analysis of the two stage mutation model in von Hippel-Lindau disease, and in sporadic cerebellar haemangioblastoma and renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21453

7 January 2021

VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21453

7 January 2021

Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: relationship to clinicopathological parameters

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21453

7 January 2021

Playing Tag with HIF: The VHL Story

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21453

7 January 2021

Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21453

7 January 2021

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21453

7 January 2021

Involvement of platelet-derived growth factor in disease: development of specific antagonists

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21453

7 January 2021

Ras regulation of vascular endothelial growth factor and angiogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21453

7 January 2021

Extracellular signal-regulated kinases 1/2 are serum-stimulated "Bim(EL) kinases" that bind to the BH3-only protein Bim(EL) causing its phosphorylation and turnover

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21453

7 January 2021

Bcl-2 targets the protein kinase Raf-1 to mitochondria

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21453

7 January 2021

Raf-1 promotes cell survival by antagonizing apoptosis signal-regulating kinase 1 through a MEK-ERK independent mechanism

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21453

7 January 2021

Raf and the road to cell survival: a tale of bad spells, ring bearers and detours

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21453

7 January 2021

Role of Raf in vascular protection from distinct apoptotic stimuli

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21453

7 January 2021

Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21453

7 January 2021

Loss of tumor suppressor protein PTEN during renal carcinogenesis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21453

7 January 2021

Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21453

7 January 2021

Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21453

7 January 2021

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21453

7 January 2021

Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21453

7 January 2021

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21453

7 January 2021

Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer a

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21453

7 January 2021

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21453

7 January 2021

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21453

7 January 2021

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21453

7 January 2021

Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21453

7 January 2021

Therapeutic potential of ABX-EGF: a fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21453

7 January 2021

Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21453

7 January 2021

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21453

7 January 2021

New target, new drug, old paradigm

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21453

7 January 2021

Identifiers

DOI

10.1002/CNCR.21453

1 reference

13 August 2017

1 reference